Announcement of the Selection Result of the Selected Providers List for the Partner Selection in the Development and Management of Environmentally Friendly Technology-Based Waste Processing Into Electricity 3-11-2025, 17:38

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

Axogen, Inc. Appoints Jens Schroeder Kemp as Chief 13-02-2023, 19:01